APOE and Alzheimer disease: We hypothesized that a combination of plasma biomarkers, as well as APOE genotype, plasma Aβ42/40 and pTau-181 would predict MCI progression to Alzheimer's disease dementia within 5 years with improved accuracy compared with demographic and clinical variables alone.